Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma

Ampersand Biosciences was cited in the article titled, “Pharmacodynamic changes in tumor and immune cells drive iberdomide’s clinical mechanisms of activity in relapsed and refractory multiple myeloma” for analyzing samples at their facility in Lake Clear, NY using Millipore kit HCD8MAG-17k 17-plex cytokine assay.

Species: Human
Focus: Myeloma